Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
Completed · Phase 2
Conditions studied: Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
In brief
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
Key facts
- Study ID
- NCT01707472
- Run by
- Gilead Sciences
- People needed
- 18
- Starts
- 2012-10-04
- Expected to finish
- 2014-10-17
- Last updated by the study team
- 2019-11-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- NIH Department of Laboratory Medicine — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.